Cargando…

Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation

Breast cancer is the most common neoplasm diagnosed in women around the world. Checkpoint inhibitors, targeting the programmed death receptor-1 or ligand-1 (PD-1/PD-L1) axis, have dramatically changed the outcome of cancer treatment. These therapies have been recently considered as alternatives for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Segovia-Mendoza, Mariana, Romero-Garcia, Susana, Lemini, Cristina, Prado-Garcia, Heriberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808819/ https://www.ncbi.nlm.nih.gov/pubmed/33506060 http://dx.doi.org/10.1155/2021/6668573

Ejemplares similares

The Interplay of GPER1 with 17β-Aminoestrogens in the Regulation of the Proliferation of Cervical and Breast Cancer Cells: A Pharmacological Approach
por: Segovia-Mendoza, Mariana, et al.
Publicado: (2022)

Epithelial-to-Mesenchymal Transition in Metastasis: Focus on Laryngeal Carcinoma
por: Goulioumis, Anastasios, et al.
Publicado: (2022)

Epithelial–mesenchymal transition in cancer
por: Moustakas, Aristidis, et al.
Publicado: (2017)

The Epithelial-to-Mesenchymal Transition (EMT), a Particular Case
por: Cebrià-Costa, Joan Pau, et al.
Publicado: (2014)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study
por: Segovia-Mendoza, Mariana, et al.
Publicado: (2015)

Vitamin D and the Epithelial to Mesenchymal Transition
por: Larriba, María Jesús, et al.
Publicado: (2016)

Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
por: Furkert, Chris, et al.
Publicado: (2023)

The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas
por: Fedele, Monica, et al.
Publicado: (2017)

Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelial–Mesenchymal Transition
por: O’Connell, Isabel, et al.
Publicado: (2023)

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
por: Soundararajan, Rama, et al.
Publicado: (2019)

Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
por: Shi, Tao, et al.
Publicado: (2018)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Revisiting mTOR and Epithelial–Mesenchymal Transition
por: Herrerias, Mariana M., et al.
Publicado: (2020)

Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-β signaling
por: Lin, Yueh-Te, et al.
Publicado: (2020)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma
por: Zhou, Yang, et al.
Publicado: (2022)

Epithelial to mesenchymal transition in tumor cells as consequence of phenotypic instability
por: García de Herreros, Antonio
Publicado: (2014)

The Transcription Factor Elf3 Is Essential for a Successful Mesenchymal to Epithelial Transition
por: Sengez, Burcu, et al.
Publicado: (2019)

Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer
por: Aghajani, Marra Jai, et al.
Publicado: (2020)

Actin cytoskeletal control during epithelial to mesenchymal transition: focus on the pancreas and intestinal tract
por: Morris, H T, et al.
Publicado: (2015)

Recent Advances in Transcription Factors Biomarkers and Targeted Therapies Focusing on Epithelial–Mesenchymal Transition
por: Chuang, Kai-Ting, et al.
Publicado: (2023)

Role of MicroRNAs in Signaling Pathways Associated with the Pathogenesis of Idiopathic Pulmonary Fibrosis: A Focus on Epithelial-Mesenchymal Transition
por: Cadena-Suárez, Ana Ruth, et al.
Publicado: (2022)

Role of DNA Methylation in the Resistance to Therapy in Solid Tumors
por: Romero-Garcia, Susana, et al.
Publicado: (2020)

Lactic Acidosis in the Presence of Glucose Diminishes Warburg Effect in Lung Adenocarcinoma Cells
por: Prado-Garcia, Heriberto, et al.
Publicado: (2020)

A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition
por: McFaline-Figueroa, José L., et al.
Publicado: (2019)

TNF-α-mediated epithelial-to-mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2020)

Stromal-Modulated Epithelial-to-Mesenchymal Transition in Cancer Cells
por: Atiya, Huda I., et al.
Publicado: (2023)

New Actors Driving the Epithelial–Mesenchymal Transition in Cancer: The Role of Leptin
por: Olea-Flores, Monserrat, et al.
Publicado: (2020)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer
por: Song, Junquan, et al.
Publicado: (2022)

The Epithelial-to-Mesenchymal Transition in Cancer
por: Roche, Joëlle
Publicado: (2018)

Cortactin in Epithelial–Mesenchymal Transition
por: Ji, Rong, et al.
Publicado: (2020)

Glycobiology of the Epithelial to Mesenchymal Transition
por: Pucci, Michela, et al.
Publicado: (2021)

Epithelial–Mesenchymal Transition (EMT)
por: Manfioletti, Guidalberto, et al.
Publicado: (2023)

Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
por: Wang, Yuqing, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

PD1(hi) CD200(hi) CD4(+) exhausted T cell increase immunotherapy resistance and tumour progression by promoting epithelial–mesenchymal transition in bladder cancer
por: Wu, Chun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_obs0d4bo5c6oeih5bpio774kij